BIO Comments for the Patient-Centered Outcomes Research Institute’s (PCORI’s) Dissemination and Implementation Roundtable

Joe V. Selby, M.D., M.P.H.

Executive Director

Patient-Centered Outcomes Research Institute

1701 Pennsylvania Ave. NW

Suite 300

Washington, DC 20006

 

RE: Patient-Centered Outcomes Research Institute’s (PCORI’s) Dissemination and Implementation Roundtable, Stakeholder Response

 

Dear Dr. Selby:

The Biotechnology Industry Organization (BIO) is pleased to submit feedback on several of the concepts proposed for discussion during PCORI’s Dissemination and Implementation Roundtable (“the Roundtable”) held on July 29, 2013 in Washington, D.C. and appreciates PCORI’s efforts to garner diverse stakeholder input for this event. BIO is the largest trade organization to serve and represent the biotechnology industry in the United States and around the globe. BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers, and related organizations in the United States. BIO members are involved in the research and development of novel interventions to prevent, treat, and cure diseases through the most advanced science.

 

BIO supports PCORI’s goal of increasing the availability of accurate, scientific evidence to inform clinical decision-making, and we maintain an ongoing desire to see PCORI successfully carry out its statutory mandate, of which dissemination of clinical comparative effectiveness research (CER) is a vital component. The stated goal for the July 29th Roundtable is to serve as the foundation for developing a “request for proposal (RFP) for the commission [of a]…PCORI Blueprint for Dissemination and Implementation of Research.” To structure that input, PCORI proposes to the public the same series of questions that will be the focus of the Roundtable discussion, including current and ideal frameworks, mechanisms, and strategies for disseminating and implementing CER. BIO submits its perspective on these issues through the following comments that address PCORI’s effort in the context of its statutory mandate and in terms of essential considerations for the appropriate communication of CER findings. These concepts are explored in detail below.